Improving Therapeutic Decisions

ETEST is a well-established method for antimicrobial susceptibility testing in microbiology laboratories around the world. ETEST consists of a predefined gradient of antibiotic concentrations on a plastic strip and is used to determine the Minimum Inhibitory Concentration (MIC) of antibiotics, antifungal agents and antimycobacterial agents.

Now FDA 510(k) Cleared!

ETEST Telavancin
(TLA 0.002-32 µg/mL)

Order online or learn more

ETEST Meropenem/vaborbactam
(MEV 0.004/8-64/8 µg/mL)

Order online or learn more!

ETEST Piperacillin/Tazobactam 
(PT 0.016/4 - 256/4 µg/mL)

Order online or learn more

ETEST Imipenem/Relebactam 
(IR 0.002/4 - 32/4 µg/mL)

Order online or learn more

ETEST Eravacycline 
(ERV 0.002 - 32 µg/mL)

Order online or learn more!

ETEST Delafloxacin
(DFX 0.002/4 - 32/4 µg/mL)

Order online or learn more!


ETEST Plazomicin
(PLZ 0.016 - 256 µg/mL)

Order online or learn more!




Quantitative MIC data is a prerequisite for the management of critical infections, including sepsis, especially among critical care patients. ETEST for antimicrobial resistance testing is particularly valuable in such situations, when on-scale MICs are needed for treatment decisions.

ETEST is recognized as a cost-effective tool for generating MICs across 15 dilutions. It can also be used in a macromethod format to optimize resistance detection. More than 100 antibiotics are now available in the product range for testing of aerobic bacteria and fastidious organisms such as Pneumococci, Haemophilus, H. pylori, Meningococci, Gonococci, anaerobes, fungi and mycobacteria.


  • Perform antibiotic susceptibility testing (AST)
  • Provide MICs for slow-growing and fastidious organisms that have unique growth requirements and cannot be tested by automated methods
  • Test robust aerobes, anaerobes, pneumococci, menigococci and fastidious organisms such as the HACEK group, Bordetella and Francisella
  • Detect and confirm phenotypic resistance
  • Confirm or detect low-level or new resistance mechanisms 
  • Enhance antimicrobial stewardship programs
  • Validate susceptibility results
  • Guide antibiotic selection and dosing
  • Improve patient outcomes and lower healthcare-associated expenses
  • Decrease hospital length of stay and associated costs of prolonged hospitalization


For an up-to-date list of available ETEST products, please refer to the Specs tab.

Features & Specs

ETEST is a well-established method for antimicrobial resistance testing that brings on-scale MIC testing to all microbiology laboratories.

ETEST promotes the rational use of antibiotics by providing results to guide the therapy of individual patients and to validate empiric drug regimens.

It is particularly helpful in determining choice and dosage of antimicrobials in patients with sterile site infections (i.e., endocarditis), severe nosocomial infections, chronic infections (i.e., cystic fibrosis) and immunosuppressed patients.

ETEST is also widely used in resistance surveillance programs and clinical trials.


ETEST Single Pack Blister

Self-contained, individually wrapped ETEST strips with desiccant.

ETEST Single Pack Blister packaging option provides the following benefits:

  • One strip per package eliminates the need to store opened strips
  • Easy to open with one hand - simply remove strip with forceps or manual applicator device
  • Standardized storage conditions (-20°C to +8°C for all antimicrobials)
  • Desiccant within each Single Pack Blister helps ensure stability
  • Clear, concise labeling on each Single Pack Blister
  • Lot number on outer box and on each individual single pack
  • Available in boxes of 30 strips

For an up-to-date list of ETEST products available:

 ETEST Catalog


To order please visit:

ETEST Application Guide

For information about the many uses of ETEST, by organism, download the ETEST Application Guide here.

ETEST Publications

Antifungal susceptibility testing:

Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006;42(7):938-944. doi: 10.1086/500939

Pseudomonas aeruginosa, Acinetobacter baumannii and Clostridium difficile:

Landman D, Bratu S, Kochar S, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother. 2007:60(1);78-82. doi: 10.1093/jac/dkm129

University of Nottingham. Waging war on the deadliest superbug. ScienceDaily. July 7, 2007. Accessed October 24, 2017.

Pseudomonas aeruginosa and Enterobacteriaceae:

ASM Microbe 2017 - Performance of ceftolozane-tazobactam ETEST for antimicrobial susceptibility testing of Pseudomonas aeruginosa and Enterobacteriaceae. University of California, Los Angeles, CA. Poster #: Friday - 424.


Rosenblatt JE. Can we afford to do anaerobic cultures and identification? A positive point of view. Clin Inf Dis. 1997;25:S127-S131.


Rosser SJ, Alfa MJ, Hoban S, Kennedy J, Harding GK. ETEST versus agar dilution for antimicrobial susceptibility testing of Viridans group streptococci. J Clin Microbiol. 1999;37(1):26-30.


Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004;48(1):275-280. doi: 10.1128/AAC.48.1.275-280.2004


Stürenburg E, Sobottka I, Noor D, Laufs R, Mack D. Evaluation of a new cefepime–clavulanate ESBL ETEST to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother. 2004;54(1):134-138. doi: 10.1093/jac/dkh274

MIC for critical infections:

Potoski BA, Mangino JE, Goff DA. Clinical failures of linezolid and implications for the clinical microbiology laboratory. Emerg Infect Dis. 2002;8(12):1519-1520. doi: 10.3201/eid0812.020139


Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39(7):2439-2444. doi: 10.1128/JCM.39.7.2439-2444.2001

Cystic fibrosis:

Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2000;38(5):1818-1822.


Chaves F, Campelo C, Sanz F, Otero JR. Meningitis due to mixed infection with penicillin-resistant and penicillin-susceptible strains of Streptococcus pneumoniae. J Clin Microbiol. 2003;41(1);512-513. doi: 10.1128/JCM.41.1.512–513.2003

Haemophilus spp.:

Pérez-Vázquez M, Román F, Varela MC, Cantón R, Campos J. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. J Antimicrobiol Chemother. 2003;51(1):147-151. doi: 10.1093/jac/dkg049


Alam MR, Donabedian S, Brown W, et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol. 2001;39(9):3379-3381. doi: 10.1128/JCM.39.9.3379-3381.2001

Gram negative non-Fermenters:

Di Bonaventura G, Ricci E, Della Loggia N, Catamo G, Piccolomini R. Evaluation of the ETEST for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with long-term bladder catheterization. J Clin Microbiol. 1998;36(3):824-826.


Jones RN, Deshpande LM, Erwin ME, Barrett MS, Beach ML. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and ETEST methods. J Antimicrob Chemother. 2000;45(supp3):67. doi: 10.1093/jac/45.suppl_3.67

For an up to date list of available Etest products, please refer to the Specs tab.

PRN 17-0206-02

Pioneering Diagnostics